Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adam Schwartz

Physician Assistant, Medical Phoenix, AZ Physician Assistant

NPI 1528121266 CMS profile 11050806

6970 E Chauncey Ln Ste 100, Phoenix, AZ 85054

Open in the dashboard

General payments

$12,391

572 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Schwartz of Phoenix, AZ is reported in the CMS Open Payments database as having received $12,391 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,649 110
2024 General $2,135 103
2023 General $3,131 145
2022 General $2,726 130
2021 General $1,750 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Schwartz
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Adam Schwartz were reported at $2,649. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Adam Schwartz Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,750 $156 $41–$563 $132
2022 $2,726 $185 $55–$649 $149
2023 $3,131 $199 $58–$717 $160
2024 $2,135 $206 $62–$740 $164
2025 $2,649 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,651 102 payments
  2. AstraZeneca Pharmaceuticals LP $1,519 59 payments
  3. Genzyme Corporation $923 43 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $693 26 payments
  5. Regeneron Healthcare Solutions, Inc. $656 28 payments
  6. Grifols USA, LLC $611 26 payments
  7. Electromed, Inc. $531 48 payments
  8. Genentech USA, Inc. $492 27 payments
  9. Actelion Pharmaceuticals US, Inc. $473 14 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $449 27 payments
  11. Other $4,393 172 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,988 561 payments
  2. Education $296 5 payments
  3. Consulting Fee $107 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,473 72 payments
  2. TRELEGY ELLIPTA $937 61 payments
  3. TEZSPIRE $822 19 payments
  4. NUCALA $756 45 payments
  5. BREZTRI $684 19 payments
  6. DUPIXENT Inflammation And Immunology $602 26 payments
  7. AIRSUPRA $575 13 payments
  8. YUPELRI $501 21 payments
  9. FASENRA $495 12 payments
  10. SMARTVEST $482 45 payments
  11. Other $8,371 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,096

Median for Physician Assistant: 241

Drug cost

$374,115

Median for Physician Assistant: $4,110

Branded share of claims

70.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 256 $191,856
Breo Ellipta Fluticasone/Vilanterol Brand 82 $43,420
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 62 $42,867
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 51 $22,671
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 30 $17,272
Symbicort Budesonide/Formoterol Fumarate Brand 36 $10,735
Incruse Ellipta Umeclidinium Bromide Brand 15 $10,558
Arnuity Ellipta Fluticasone Furoate Brand 21 $9,176
Qvar Redihaler Beclomethasone Dipropionate Brand 17 $7,203
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 11 $4,584

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $209
$209 — —
DUPIXENT
  • GENZYME CORPORATION $151
  • Regeneron Healthcare Solutions, Inc. $44
$195 — —
XOLAIR
  • Genentech USA, Inc. $101
  • Novartis Pharmaceuticals Corporation $61
$162 — —
Sunosi
  • Axsome Therapeutics, Inc. $157
$157 — —
Hizentra
  • CSL Behring $148
$148 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record